Advertisement

Topics

Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?

17:19 EDT 12 Jul 2018 | SCRIP

A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review...

      

Related Stories

 

Original Article: Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?

NEXT ARTICLE

More From BioPortfolio on "Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...